Amgen’s Rare Disease Portfolio Grows With Second Approved Uplizna Indication

Generalized Myasthenia Gravis Could Be Third

 
• By Mandy Jackson
  
Uplizna's approval in IgG4-RD adds to the rare disease foundation Amgen built with its Horizon acquisition (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Strategy

More from Scrip